As of 2025-11-17, the Intrinsic Value of Rua Life Sciences PLC (RUA.L) is 17.15 GBP. This RUA.L valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 12.25 GBP, the upside of Rua Life Sciences PLC is 40.00%.
The range of the Intrinsic Value is 16.04 - 19.93 GBP
Based on its market price of 12.25 GBP and our intrinsic valuation, Rua Life Sciences PLC (RUA.L) is undervalued by 40.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (60.77) - (27.37) | (37.85) | -409.0% |
| DCF (Growth 10y) | (23.18) - (45.53) | (30.30) | -347.3% |
| DCF (EBITDA 5y) | 16.04 - 19.93 | 17.15 | 40.0% |
| DCF (EBITDA 10y) | 29.59 - 41.35 | 33.52 | 173.6% |
| Fair Value | -0.08 - -0.08 | -0.08 | -100.63% |
| P/E | (0.41) - 2.29 | 0.84 | -93.1% |
| EV/EBITDA | 10.70 - 17.49 | 14.08 | 14.9% |
| EPV | (16.96) - (21.94) | (19.45) | -258.8% |
| DDM - Stable | (0.13) - (0.36) | (0.25) | -102.0% |
| DDM - Multi | 5.44 - 11.66 | 7.44 | -39.3% |
| Market Cap (mil) | 7.91 |
| Beta | 0.60 |
| Outstanding shares (mil) | 0.65 |
| Enterprise Value (mil) | 5.37 |
| Market risk premium | 5.98% |
| Cost of Equity | 10.01% |
| Cost of Debt | 5.00% |
| WACC | 9.35% |